Literature DB >> 1637880

Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events.

V Runde1, C Aul, T Südhoff, A Heyll, W Schneider.   

Abstract

The clinical course of three patients with acute promyelocytic leukemia receiving all-trans retinoic acid (ATRA) as a single agent is reported. The first two patients were in first and second relapse of their leukemia that had occurred despite maintenance treatment with 13-cis retinoic acid after chemotherapy-induced complete remission (CR). A switch to ATRA was followed by achievement of a CR in two patients. The third patient received ATRA as first-line therapy. Two patients experienced thromboembolic complications during the phase of ATRA-induced leukocytosis. One of them died of pulmonary embolism on day 16 of treatment. The two responding patients who did not receive consolidation chemotherapy relapsed after 6 and 9 months, respectively. Increase of the ATRA dose failed to induce a new remission.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1637880     DOI: 10.1007/bf01695469

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

1.  Treatment of acute promyelocytic leukemia with all-trans retinoic acid.

Authors:  P Fenaux; L Degos
Journal:  Leuk Res       Date:  1991       Impact factor: 3.156

2.  Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid.

Authors:  L Degos; C Chomienne; M T Daniel; R Berger; H Dombret; P Fenaux; S Castaigne
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

3.  Retinoic acid therapy for promyelocytic leukaemia.

Authors:  C Chomienne; P Ballerini; N Balitrand; M Amar; J F Bernard; P Boivin; M T Daniel; R Berger; S Castaigne; L Degos
Journal:  Lancet       Date:  1989-09-23       Impact factor: 79.321

4.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.

Authors:  S Castaigne; C Chomienne; M T Daniel; P Ballerini; R Berger; P Fenaux; L Degos
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

5.  All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship.

Authors:  C Chomienne; P Ballerini; N Balitrand; M T Daniel; P Fenaux; S Castaigne; L Degos
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

6.  Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China.

Authors:  Z Y Wang; G L Sun; J X Lu; L J Gu; M E Huang; S R Chen
Journal:  Nouv Rev Fr Hematol       Date:  1990

7.  A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients.

Authors:  Z X Chen; Y Q Xue; R Zhang; R F Tao; X M Xia; C Li; W Wang; W Y Zu; X Z Yao; B J Ling
Journal:  Blood       Date:  1991-09-15       Impact factor: 22.113

8.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

9.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

Authors:  R P Warrell; S R Frankel; W H Miller; D A Scheinberg; L M Itri; W N Hittelman; R Vyas; M Andreeff; A Tafuri; A Jakubowski
Journal:  N Engl J Med       Date:  1991-05-16       Impact factor: 91.245

10.  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.

Authors:  J Muindi; S R Frankel; W H Miller; A Jakubowski; D A Scheinberg; C W Young; E Dmitrovsky; R P Warrell
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

  10 in total
  4 in total

Review 1.  Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.

Authors:  Guang-Biao Zhou; Ji Zhang; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

2.  Acute myocardial/cerebral infarction as first/relapse manifestation in one acute promyelocytic leukemia patient.

Authors:  Ying Li; Shanshan Suo; Liping Mao; Lei Wang; Chunmei Yang; Weilai Xu; Yinjun Lou; Wenyuan Mai
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 3.  Retinoic acid and arsenic for treating acute promyelocytic leukemia.

Authors:  Guang-Biao Zhou; Wei-Li Zhao; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  PLoS Med       Date:  2005-01       Impact factor: 11.069

Review 4.  Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review.

Authors:  Damien Bouriez; Julie Giraud; Caroline Gronnier; Christine Varon
Journal:  Int J Mol Sci       Date:  2018-10-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.